Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 INOVIO, Coherus Enter Cancer Drug Combo Clinical Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

INOVIO, Coherus Enter Cancer Drug Combo Clinical Collaboration

To evaluate INO-3112 and LOQTORZI as a potential treatment for HPV16/18 positive throat cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

INOVIO, a biotechnology company developing DNA medicines to help treat and protect people from HPV-associated diseases, entered a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer commonly known as throat cancer.
 
Coherus will provide LOQTORZI for a Phase 3 trial to be conducted by INOVIO. LOQTORZI is a PD-1 inhibitor recently approved by the FDA for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma (R/P NPC).
 
“We are very pleased to be collaborating with Coherus on this novel combination therapy and are excited about the opportunity to build on encouraging data from our previous trials involving INO-3112 in HPV-related head and neck cancer,” said INOVIO’s President and Chief Executive Officer, Dr. Jacqueline Shea. “There is unique potential in combining our DNA medicines platform, which a growing body of research indicates is adept at fighting HPV-related diseases, with a proven PD-1 inhibitor to improve clinical outcomes for patients.”
 
“We are delighted to be partnering with INOVIO on the development of the toripalimab/INO-3112 combination in HPV-related OPSCC, a tumor type that is synergistic to the current toripalimab indication in R/P NPC,” said Rosh Dias, M.D., Chief Medical Officer at Coherus. “With its differentiated mechanism of action, toripalimab in combination with the INO-3112 vaccine may hold promise for these patients in earlier-stage disease, where treatment options are more limited.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics